1. No category

PROGRAMME
WCO-IOF-ESCEO
MILAN 2015
WORLD CONGRESS ON OSTEOPOROSIS,
O S T E OA RT H R I T I S A N D M U S C U L O S K E L E TA L DI S E A S E S
MARCH 26-29, 2015 | MILAN ITALY
MiCo - Fiera Milano Congressi
www.wco-iof-esceo.org
Organized by Sinklar Conference Management B.V.
2
WCO-IOF-ESCEO MILAN 2015
GENERAL INFORMATION
EVENT
World Congress on Osteoporosis, Osteoarthritis
and Musculoskeletal Diseases
DATES
March 26-29, 2015
Early Registration
< December 5, 2014
IOF Member 735 €
Non-Member 795 €
Student 250 €
Pre-registration
< December 5, 2014 - March 5, 2015 >
IOF Member 795 €
Non-Member 895 €
Student 270 €
CONGRESS VENUE
MiCo - Fiera Milano Congressi
Via Gattamelata 5 - Gate 14
20149 Milan, Italy
www.micmilano.it
CONGRESS SECRETARIAT
Yolande Piette Communication
Bd G. Kleyer, 108 | 4000 Liège - Belgium
Tel: +32 (0)4 254 12 25 | Fax: +32 (0)4 254 12 90
E-mail: [email protected]
www.piettecommunication.com
CONGRESS ORGANISER
SINKLAR Conference Management B.V.
Hogehilweg 5E,
1101CA Amsterdam Zuidoost - Netherlands
E-mail: [email protected]
CONGRESS WEBSITE
www.wco-iof-esceo.org
REGISTRATION
On Site
IOF Member 995 €
Non-Member 995 €
Student 300 €
DEADLINES
Registration cancellation:
within June 30, 2014, 50% of the registration fee will be
refunded. After this date, no refund will be possible for
cancellations.
Submission of abstracts:
January 15, 2015
Notification to the contributors:
February 13, 2015
WCO-IOF-ESCEO MILAN 2015
1
SCIENTIFIC INFORMATION
CONGRESS CHAIRMEN
John A. KANIS - IOF President
Jean-Yves REGINSTER - ESCEO President
SCIENTIFIC COMMITTEE
Cyrus COOPER
Chair, IOF Committee Scientific Advisors (CSA)
René RIZZOLI
Chair, ESCEO Scientific Advisory Board (SAB)
John A. KANIS
IOF President
Jean-Yves REGINSTER
ESCEO President
SCIENTIFIC ADVISORY BOARD
Donato AGNUSDEI,
Kristina AKESSON,
Maurice AUDRAN,
Jean-Jacques BODY,
Mary BOUXSEIN,
Maria Luisa BRANDI,
Olivier BRUYERE,
Nansa BURLET,
Etienne CAVALIER,
Claus CHRISTIANSEN,
Juliet COMPSTON,
Cyrus COOPER,
Bernard CORTET,
Jean-Pierre DEVOGELAER,
Andrea GASPARIK,
Nicholas HARVEY,
Mickaël HILIGSMANN,
John A. KANIS,
Jean-Marc KAUFMAN,
Paul LIPS,
Roman LORENC,
George LYRITIS,
Johanne MARTEL-PELLETIER,
Eugene McCLOSKEY,
Socrates PAPAPOULOS,
Karel PAVELKA,
Jean-Pierre PELLETIER,
Jean-Yves REGINSTER,
Johann RINGE,
René RIZZOLI,
Christian ROUX,
Pavel SZULC,
Thierry THOMAS.
2
LOCAL ORGANIZING COMMITTEE
Maria Luisa BRANDI (chair, LOC)
Emanuela BAIO DOSSI,
Maria Luisa BIANCHI,
Paolo CHERUBINO,
Gaetano CREPALDI,
Claudio CRICELLI,
Maurizio CUTOLO,
Andrea GENAZZANI,
Giancarlo ISAIA,
Andrea LENZI,
Stefania MAGGI,
Marco MATUCCI-CERINIC,
Roberto MESSINA,
Ranuccio NUTI,
Sergio ORTOLANI.
WCO-IOF-ESCEO MILAN 2015
WCO-IOF-ESCEO MILAN 2015
3
4
WCO-IOF-ESCEO MILAN 2015
15.30-17.30
Italian Session jointly organized by F.I.R.M.O. and E.S.C.E.O.
Chairperson: Maria‑Luisa Brandi
Palazzo delle Stelline
17.30-18.30
Best clinical papers published in 2014
René Rizzoli
Palazzo delle Stelline
18.30-20.05
WCO-IOF-ESCEO - OPENING CEREMONY
Chairpersons: John A. Kanis, Jean‑Yves Reginster
18.30-18.45
Population ageing and health: the importance of policies to
Palazzo delle Stelline
tackle musculoskeletal diseases
Islene Araujo de Carvalho (World Health Organization – Geneva)
18.45-18.50
Opening of the meeting
18.50-19.50
IOF-ESCEO-SERVIER HONORARY LECTURE
- Historical genetics of wine grapes - José Vouillamoz
Palazzo delle Stelline
Palazzo delle Stelline
19.50-20.00
Presentation of the ESCEO-IOF Servier Pierre D. Delmas Prize
Palazzo delle Stelline
20.00-20.05
Presentation of the ESCEO IOF Herbert Fleisch Medal
Palazzo delle Stelline
20.05-21.05
INDUSTRY-SPONSORED WELCOME COCKTAIL
Palazzo delle Stelline
5
08.00-09.00
NON-SPONSORED SYMPOSIUM
Application of Shape and Appearance Models in
Blue 1
Osteoporosis and Osteoarthritis
Chairperson: John Sheperd
- Introduction to Statistical Appearance Modeling for Bone Applications
- Tim Cootes
- 3D to 2D and back again: registration and modeling of 3D bone from
2D images for osteoporosis applications - Kenneth Poole
- 3D Shape Characteristics of Arthritic Bone - Tuhina Neogi
- 3D femur shape and appearance for fracture prediction - Is it ready for
clinical applications? - Oleg Museyko
Targeting Osteosarcopenia: a practical approach for the Blue 2
prevention of falls and osteoporotic fractures
Chairperson: Neil Binkley
- Introduction - Neil Binkley
- Pathophysiology of osteosarcopenia: Common mechanisms and
pathways - Gustavo Duque
- How to diagnose osteosarcopenia? - Bjoern Buering
- Therapeutic interventions for osteosarcopenia - Christina Alonso
The personal and societal burden of Osteoarthritis:
Yellow 1
observations from EPOSA
Chairperson: Elaine M. Dennison
- Introduction - Elaine M. Dennison
- Osteoarthritis and comorbidities as determinants of disability in older
populations - Stefania Maggi
- Physical performance in later life and its relationship with
Osteoarthritis - Mark Edwards
- Frailty syndrome prevalence and slow walk speed in Osteoarthritis Angel Otero
- The neighbourhood environment and use of neighbourhood resources in
older people with and without Osteoarthritis - Erik Timmermans
IOF WORKSHOP
Calcium Supplementation: Does Protecting Against
Yellow 2
Fracture Risk Increase the Risk of Cardio-vascular Diseases ?
Chairperson: Taylor C. Wallace
- Calcium Supplementation and the Risk of Cardiovascular Events Andrea Singer
- The Role of Calcium Supplementation in Coronary Artery Disease: What
is the Evidence? - Stephen Kopecky
08.30-09.00
SPECIAL EDUCATIONAL LECTURE
- Unexpected non bone effects of vitamin D - Maurizio Cutolo
White 1
09.00-10.20
SCIENTIFIC SESSION I
Chairpersons: John A. Kanis, Jean‑Yves Reginster
INDUSTRY-SPONSORED LUNCH SYMPOSIUM
Auditorium B
Calcium and vitamin D – Fact and fiction
Chairperson: John A. Kanis
- Welcome and introduction - John A. Kanis
- Efficacy of calcium and vitamin D supplementation: Where are we now?
- Cyrus Cooper
- Calcium and vitamin D supplementation: Update on safety profile René Rizzoli
- Bone protective therapies with and without calcium and vitamin D –
Does it matter? - Bess Dawson‑Hughes
- Meeting summary and close - John A. Kanis
14.00-14.30
Oral presentation of selected posters
Chairperson: Johanne Martel‑Pelletier
14.00-15.00
Poster Viewing Session I
Poster area
EDUCATIONAL LECTURE 1
Auditorium B
- How to apply for a job in a pharmaceutical company - Lucio C. Rovati
ESCEO SYMPOSIA
Revision of the guidelines for the registration of drugs Blue 1
to be used in the treatment of Osteoarthritis
Chairpersons: Andrea Laslop, Susanne Reiter‑Niesert
- Welcome and introduction - Andrea Laslop
- Current regulatory requirements for registration of drugs to be used in
osteoarthritis in Europe and need for clarification - Jean‑Yves Reginster
- Suggested clarification by the ESCEO working group - Francis Berenbaum
- Discussion - Leader: Stefania Maggi
- Conclusions and wrap-up - Andrea Laslop
Panel: Francis Berenbaum, Jaime Branco, Maria‑Luisa Brandi,
Olivier Bruyère, Cyrus Cooper, Jean‑Pierre Devogelaer,
Gabriel Herrero‑Beaumont, John A. Kanis, Andrea Laslop, Stefania Maggi,
Jean‑Yves Reginster, Susanne Reiter‑Niesert, René Rizzoli
Improving Osteoporosis Care with Trabecular Bone
Blue 2
Structure (TBS)
Chairpersons: David L. Kendler, Claus Glüer
- Welcome and introduction - Claus Glüer
- TBS in fracture risk assessment - Nicholas Harvey
- Other potential applications of TBS - Neil Binkley
- Discussion leaders - Claus Glüer - John A. Kanis
- Conclusions - John A. Kanis
Panel: Neil Binkley, Maria‑Luisa Brandi, Bruno Camargos, Cyrus Cooper,
Claus Glüer, John A. Kanis, David L. Kendler, Olivier Lamy, Andrea Laslop,
Jean‑Yves Reginster, René Rizzoli
MEET-THE-EXPERT SESSIONS
Sequential/combined therapies in Osteoporosis
Serge Ferrari
Yellow 3
09.00-09.30
Plenary Lecture 1
Auditorium A
- Osteoporosis and Sarcopenia: two disorders or one? - Roger Fielding
Monitoring of Osteoporosis treatments
Jonathan D. Adachi
Yellow 2
09.30-10.20
Oral communications selected from abstracts
Exercise, nutrition, bone and muscles
Bess Dawson‑Hughes
Yellow 1
10.20-11.45
SCIENTIFIC SESSION II
Chairpersons: Cyrus Cooper, Jean‑Pierre Pelletier
Epidemiology and management of post-menopausal
Osteoporosis in Latin America
Patricia Clark
10.20-10.50
Plenary Lecture 2
- Management of Osteoporosis in Renal Failure Marie‑Hélène Lafage‑Proust
G enetic markers for the prediction of fragility fractures White 2
Fernando Rivadeneira
10.50-11.00
Presentation of the ESCEO-MSD Fellowships
Auditorium A
15.00-16.40
SCIENTIFIC SESSION III
Chairpersons: René Rizzoli, Olivier Bruyère
Auditorium A
11.00-11.50
Oral communications selected from abstracts
12.15-13.45
INDUSTRY-SPONSORED LUNCH SYMPOSIUM
Auditorium A
15.00-15.30
Plenary Lecture 3
Auditorium A
- Bone anabolic therapies in Osteoporosis - Socrates Papapoulos
15.30-15.40
Presentation of the IOF President’s Awards
15.40-16.40
Oral communications selected from abstracts
6
White 1
Auditorium A
17.00-18.30
INDUSTRY-SPONSORED SATELLITE SYMPOSIUM
Auditorium B
Evolving Strategies for Management of Osteoporosis
Chairperson: Silvano Adami
- Opening Remarks - Silvano Adami
- The Role of Cathepsin K in Bone Homeostasis - Ego Seeman
- Odanacatib Antifracture Efficacy in Postmenopausal Women; Results From the Phase
3 Long-term Odanacatib Fracture Trial (LOFT) - Michael R. McClung
- Safety and Tolerability of Odanacatib in Post-Menopausal Women; Interim Results
From the Phase 3 Long-term Odanacatib Fracture Trial (LOFT) - Socrates Papapoulos
- Closing - Panel Question and Answer - Silvano Adami
INDUSTRY-SPONSORED SATELLITE SYMPOSIUM
Blue 1
Management of severe osteoporosis: personnalized medicine in practice
Chairpersons: Maria‑Luisa Brandi, Jean‑Yves Reginster
- Introduction - Maria‑Luisa Brandi
- Why is severe Osteoporosis still an unmet medical need 40 years after the discovery
of the first drugs? - Maria‑Luisa Brandi
- Management of patients contra-indicated or not tolerant to anti-resorptive
treatments - René Rizzoli
- New indication and safety of strontium ranelate: a comprehensive review Cyrus Cooper
- Conclusion - Jean‑Yves Reginster
7
08.00-09.00
IOF WORKSHOPS
EDUCATIONAL LECTURE 2
- How to write a grant? - Ego Seeman
Bone and Diabetes: Diabetes and Skeletal challenges
Chairpersons: Massimo Massi Benedetti, Cyrus Cooper
- Epidemiology of Diabetes and Osteoporosis - Bo Abrahamsen
- Pathophysiology of Diabetoporosis - Serge Ferrari
- New Diabetes Treatments and Bone - Nicola Napoli
Blue 2
MH T : Menopausal H ormone Therapy revisited
Yellow 1
Chairpersons: René Rizzoli, Bess Dawson‑Hughes
- Menopause: consequences and overall management - John C. Stevenson
- MHT: risks and benefits from the IMS perspective - Tobie De Villiers
- SERM/HRT combinations - Peyman Hadji
NON-SPONSORED SYMPOSIUM
H ands-on on DXA acquisition and analysis: artifactual
pitfalls and possible escapes
Blue 1
Auditorium B
ESCEO SYMPOSIUM
European perspective of the new guidelines for the
Blue 2
management of Osteoarthritis – focus on SYSADOAs
Chairpersons: Jean‑Pierre Devogelaer, Gabriel Herrero‑Beaumont
- Introduction and scope of the problem - Marc Hochberg
- Glucosamine and chondroitin salts in the management of osteoarthritis
in Europe - Jean‑Yves Reginster
- Hyaluronic acid salts in the management of Osteoarthritis in Europe Jean‑Pierre Pelletier
- Discussion - Leader: Jaime Branco
Panel: Jaime Branco, Maria‑Luisa Brandi, Olivier Bruyère, Cyrus Cooper,
Jean‑Pierre Devogelaer, Gabriel Herrero‑Beaumont, Marc Hochberg,
John A. Kanis, Emmanuel Maheu, Jean‑Pierre Pelletier,
Jean‑Yves Reginster, René Rizzoli
MEET-THE-EXPERT SESSIONS
The nutritional approach to weight management and
Yellow 2
musculoskeletal health
Chairpersons: René Rizzoli, Jean‑Jacques Body
- The benefits of yogurt to manage weight and metabolic diseases Arne Astrup
- Dairies and sustainable musculoskeletal health - René Rizzoli
Diagnosis and treatment of sarcopenia
Marjolein Visser
Yellow 2
Physical rehabilitation: which method?
Olivier Bruyère
White 2
09.00-10.20
SCIENTIFIC SESSION IV
Chairpersons: Maria‑Luisa Brandi, Stefania Maggi
Use of FRAX worldwide: current challenges and
solutions
John A. Kanis
09.00-09.30
Plenary Lecture 4
Auditorium A
- Can we alter the natural history of Osteoarthritis? - Marc Hochberg
Epidemiology and management of post-menopausal
Osteoporosis in Middle East
Leith Zakraoui
White 1
09.30-09.40
Presentation of the IOF Medal of Achievement
Management of pain in osteoporosis
Maria‑Luisa Brandi
Level -1
Auditorium A
09.40-10.20
Oral communications selected from abstracts
15.00-16.40
SCIENTIFIC SESSION VI
Chairpersons: Johanne Martel‑Pelletier, Marc Hochberg
10.50-11.45
SCIENTIFIC SESSION V
Chairpersons: Jean‑Marc Kaufman, Socrates Papapoulos
10.20-10.50
Plenary Lecture 5
Auditorium A
- Is it time to resurrect menopause hormone therapy in Osteoporosis? John C. Stevenson
10.50-11.45
Oral communications selected from abstracts
12.15-13.45
INDUSTRY-SPONSORED LUNCH SYMPOSIUM
Auditorium B
Dairy products & bone health : turning facts and beliefs into clinical
practice
Chairpersons: Jean‑Yves Reginster, René Rizzoli
- The acid-ash hypothesis and bone health - Tanis Fenton
- Dairy consumption, prevention of osteoporosis & fractures: an update Olivier Bruyère
- Dairy product facts & fiction - Jean‑Jacques Body
INDUSTRY-SPONSORED LUNCH SYMPOSIUM
Auditorium A
Putting the Patient First: Effective Management Strategies to Reduce the
Burden of Osteoporosis
Chairperson: Maria‑Luisa Brandi
- Welcome & Introduction - Maria‑Luisa Brandi
- Bridging the Osteoporosis Care Gap: Improving Patient Outcomes with a
Fracture Liaison Service - Maria‑Luisa Brandi
- Understanding the Fragile Patient: Identifying and Addressing the
Clinical Challenge - Astrid Fahrleitner‑Pammer
- Preventing Secondary Osteoporosis: Anabolic vs Anti-resorptive Therapy
for Improving Patient Outcomes - Erik Fink Eriksen
- Question & Answer. Symposium Close - Maria‑Luisa Brandi
14.00-14.30
Oral presentation of selected posters
Chairperson: Johanne Martel‑Pelletier
14.00-15.00
Poster Viewing Session II
8
Yellow 3
Poster area
15.00-15.30
Plenary Lecture 6
Auditorium A
- How long should we treat osteoporotic patients? - Maria‑Luisa Brandi
15.30-16.40
Oral communications selected from abstracts
15.00-17.00
COMMITTEE OF NATIONAL SOCIETIES SPECIAL PLENARY SESSION
Healthy Life, Healthy Bones
Chairpersons: Jean‑Yves Reginster, Judy Stenmark
16.50-17.00
Presentation of the IOF Committee of National Societies Medal
Yellow 1
17.00-18.00
ESCEO-EUGMS SYMPOSIUM
Can we identify which patients should be treated in
Blue 1
Osteoarthritis?
Chairpersons: Johanne Martel‑Pelletier, Olivier Bruyère
- Welcome and introduction - Marc Hochberg
- The need for phenotyping patients in Osteoarthritis - Nigel K. Arden
- Is it possible to phenotype patients in Osteoarthritis? - Olivier Bruyère
- Discussion - ‑
- Wrap up and conclusions - Olivier Bruyère
Panel: Nigel K. Arden, Francis Berenbaum, Jaime Branco,
Maria‑Luisa Brandi, Olivier Bruyère, Philip Conaghan, Cyrus Cooper,
Elaine M. Dennison, Jean‑Pierre Devogelaer, Gabriel Herrero‑Beaumont,
Marc Hochberg, John A. Kanis, Stefania Maggi, Johanne Martel‑Pelletier,
Jean‑Pierre Pelletier, Susanne Reiter‑Niesert, Jean‑Yves Reginster,
René Rizzoli
IOF WORKSHOP
ISCD-IOF Joint Session : Latest trends on secondary
Blue 2
fracture prevention
Chairpersons: Neil Binkley, Kristina Akesson
- Capture the fracture -update - Cyrus Cooper
- Novel diagnostic technologies - H.P. Dimai
- Laboratory Work-up Post Hip Fracture Repair, What to Measure and
When, the Impact of Surgery on Laboratory Results - Neil Binkley
17.00-18.30
INDUSTRY-SPONSORED SATELLITE SYMPOSIUM
Auditorium B
Hypophosphatasia: a rare disease with heterogeneous presentation
Chairperson: Maria‑Luisa Bianchi
- Introduction - Maria‑Luisa Bianchi
- Characterizing the burden of disease in patients with HPP - Thomas Weber
- Clinical presentation of HPP in a family with the same mutation: heterogeneous or
homogeneous phenotype? - Francesco Conti
- Differentiating HPP from other musculoskeletal diseases - Christian Roux
INDUSTRY-SPONSORED SATELLITE SYMPOSIUM
Auditorium A
9
08.00-09.00
NON-SPONSORED SYMPOSIUM
Clinical Application of Bone Microindentation
Blue 1
Osteogenic Loading, Low-Impact, H igh Loading stimulus for Bone Yellow 2
Density Development
Links between atherosclerosis and osteoporosis
Chairpersons: Sekib Sokolovic, Roberto Jacomelli, Almira Hadzovic‑Dzuvo
- Atherosclerosis: Degenerative or Inflammatory disease - Dragan Lovic
- Osteoporosis: Degenerative or Inflammatory disease - Ülke Akarirmak
- Atherosclerosis and Osteoporosis: Is there are any link? - Sekib Sokolovic
Blue 2
Non-holiday drug for osteoporosis. Is it possible to calculate the Yellow 1
economic impact of anti fracture efficacy versus side effect ?
Chairperson: Elio Tanaka
- Introduction - Elio Tanaka
- The drugs for osteoporosis , past , present and future - Fernanda Tanaka
- The anti fracture efficacy and the adverse effects of the osteoporosis´drugs . Claudia Totsugui Mariano
- The economic impact of anti fracture efficacy versus side or adverse effects Alexander Itria
- The drug for bone event specialy in dismetabolic patients , like chronic kidney
failure group of patients - Fabiana Gatti de Menezes
- Questions and closing remarks - Elio Tanaka
09.00-10.50
SCIENTIFIC SESSION VII
Chairpersons: Roger Fielding, Nicholas Harvey
09.00-09.30
Plenary Lecture 7
- Inflammation and bone fragility - Christian Roux
09.30-09.40
Presentation of the IOF Olof Johnell Science Award
Auditorium A
Auditorium A
09.40-10.20
Oral communications selected from abstracts
10.20-10.50
Plenary Lecture 8
Auditorium A
- Guidelines diversity in glucocorticoid-induced Osteoporosis - Cyrus Cooper
10.50-11.50
ESCEO SYMPOSIUM
G uidelines for the registration of drugs to be used in frailty and
sarcopenia
Chairpersons: Alfonso Cruz Jentoft, Marjolein Visser
- Introduction - René Rizzoli
- Who should we treat in Sarcopenia - Antonio Cherubini
- How to assess diseases in Sarcopenia - Roger Fielding
- Discussion leaders - Ivan Bautmans - Luc J. C. van Loon
- Conclusion - Jean‑Yves Reginster
Panel: Islene Araujo de Carvalho (World Health Organization – Geneva),
Ivan Bautmans, Heike Bischoff‑Ferrari, Maria‑Luisa Brandi, Olivier Bruyère,
Etienne Cavalier, Antonio Cherubini, Cyrus Cooper, Gaetano Crepaldi,
Alfonso Cruz Jentoft, Roger Fielding, John A. Kanis, Alberto Pilotto,
Jean‑Yves Reginster, Susanne Reiter‑Niesert, René Rizzoli, Serge Rozenberg
12.15-13.45
INDUSTRY-SPONSORED LUNCH SYMPOSIUM
INDUSTRY-SPONSORED LUNCH SYMPOSIUM
10
Blue 1
T hu r s d ay , M ar c h 2 6
18.50-19.50
SERVIER HONORARY LECTURE
- Historical genetics of wine grapes - José Vouillamoz
20.05-21.05
MEDA AB WELCOME COCKTAIL
Palazzo delle Stelline
Palazzo delle Stelline
F r i d ay , M ar c h 2 7
12.15-13.45
MEDA AB LUNCH SYMPOSIUM
Auditorium A
TAKEDA LUNCH SYMPOSIUM
Auditorium B
Calcium and vitamin D – Fact and fiction
Chairperson: John A. Kanis
- Welcome and introduction - John A. Kanis
- Efficacy of calcium and vitamin D supplementation: Where are we now? Cyrus Cooper
- Calcium and vitamin D supplementation: Update on safety profile - René Rizzoli
- Bone protective therapies with and without calcium and vitamin D – Does it
matter? - Bess Dawson‑Hughes
- Meeting summary and close - John A. Kanis
17.00-18.30
MSD SATELLITE SYMPOSIUM
Auditorium B
Evolving Strategies for Management of Osteoporosis
Chairperson: Silvano Adami
- Opening Remarks - Silvano Adami
- The Role of Cathepsin K in Bone Homeostasis - Ego Seeman
- Odanacatib Antifracture Efficacy in Postmenopausal Women; Results From the Phase
3 Long-term Odanacatib Fracture Trial (LOFT) - Michael R. McClung
- Safety and Tolerability of Odanacatib in Post-Menopausal Women; Interim Results
From the Phase 3 Long-term Odanacatib Fracture Trial (LOFT) - Socrates Papapoulos
- Closing - Panel Question and Answer - Silvano Adami
SERVIER SATELLITE SYMPOSIUM
Blue 1
Management of severe osteoporosis: personnalized medicine in practice
Chairpersons: Maria‑Luisa Brandi, Jean‑Yves Reginster
- Introduction - Maria‑Luisa Brandi
- Why is severe Osteoporosis still an unmet medical need 40 years after the discovery
of the first drugs? - Maria‑Luisa Brandi
- Management of patients contra-indicated or not tolerant to anti-resorptive
treatments - René Rizzoli
- New indication and safety of strontium ranelate: a comprehensive review Cyrus Cooper
- Conclusion - Jean‑Yves Reginster
Satu r d ay , M ar c h 2 8
12.15-13.45
CERIN / CNIEL, EMF, GDP LUNCH SYMPOSIUM
Auditorium B
Dairy products & bone health : turning facts and beliefs into clinical practice
Chairpersons: Jean‑Yves Reginster, René Rizzoli
- The acid-ash hypothesis and bone health - Tanis Fenton
- Dairy consumption, prevention of osteoporosis & fractures: an update Olivier Bruyère
- Dairy product facts & fiction - Jean‑Jacques Body
ELI LILLY LUNCH SYMPOSIUM
Auditorium A
Putting the Patient First: Effective Management Strategies to Reduce the Burden of
Osteoporosis
Chairperson: Maria‑Luisa Brandi
- Welcome & Introduction - Maria‑Luisa Brandi
- Bridging the Osteoporosis Care Gap: Improving Patient Outcomes with a Fracture
Liaison Service - Maria‑Luisa Brandi
- Understanding the Fragile Patient: Identifying and Addressing the Clinical Challenge
- Astrid Fahrleitner‑Pammer
- Preventing Secondary Osteoporosis: Anabolic vs Anti-resorptive Therapy for
Improving Patient Outcomes - Erik Fink Eriksen
- Question & Answer. Symposium Close - Maria‑Luisa Brandi
11
17.00-18.30
AMGEN SATELLITE SYMPOSIUM
Auditorium A
ALEXION SATELLITE SYMPOSIUM
Auditorium B
Hypophosphatasia: a rare disease with heterogeneous presentation
Chairperson: Maria‑Luisa Bianchi
- Introduction - Maria‑Luisa Bianchi
- Characterizing the burden of disease in patients with HPP - Thomas Weber
- Clinical presentation of HPP in a family with the same mutation: heterogeneous or
homogeneous phenotype? - Francesco Conti
- Differentiating HPP from other musculoskeletal diseases - Christian Roux
12
12/01/2015